TY - GEN
T1 - Molecular ultrasound imaging of tumor response to bevacizumab using a breast cancer animal model
AU - Sorace, Anna G.
AU - Saini, Reshu
AU - Mahoney, Marshall J.
AU - Umphrey, Heidi
AU - Hoyt, Kenneth
PY - 2012
Y1 - 2012
N2 - Ultrasound (US) contrast agents, or microbubbles (MBs), have shown immense potential in cancer detection, staging and monitoring drug treatment. Contrast-enhanced US imaging utilizes non-linear oscillations of MBs to improve signal detection from the vasculature. Targeted MBs to overexpressed receptors in a region-of-interest allow enhancement of intratumoral visualization of vasculature. This permits longitudinal studies of angiogenesis development and shows potential in analyzing tumor response to therapy. In this study, breast cancer-bearing mice were analyzed using molecular US imaging for early response to bevacizumab, a vascular disrupting agent. Mice were injected systemically with MBs targeted simultaneously to VEGFR2, p-selectin and αVβ 3. Mice underwent molecular US imaging and were analyzed for changes in intratumoral enhancement after delivery of bevacizumab. Individual animal response to therapy was analyzed and established as a 10% or greater reduction in intratumoral enhancement by day 3 post therapy. Intratumoral enhancement was assessed using custom Matlab software. Therapeutic group animals showed a significant response to drug compared to the control group by day 3 (P < 0.01). Molecular US imaging is a non-invasive, inexpensive approach for analyzing early response to vascular disrupting agents as demonstrated by this study in a breast cancer animal model.
AB - Ultrasound (US) contrast agents, or microbubbles (MBs), have shown immense potential in cancer detection, staging and monitoring drug treatment. Contrast-enhanced US imaging utilizes non-linear oscillations of MBs to improve signal detection from the vasculature. Targeted MBs to overexpressed receptors in a region-of-interest allow enhancement of intratumoral visualization of vasculature. This permits longitudinal studies of angiogenesis development and shows potential in analyzing tumor response to therapy. In this study, breast cancer-bearing mice were analyzed using molecular US imaging for early response to bevacizumab, a vascular disrupting agent. Mice were injected systemically with MBs targeted simultaneously to VEGFR2, p-selectin and αVβ 3. Mice underwent molecular US imaging and were analyzed for changes in intratumoral enhancement after delivery of bevacizumab. Individual animal response to therapy was analyzed and established as a 10% or greater reduction in intratumoral enhancement by day 3 post therapy. Intratumoral enhancement was assessed using custom Matlab software. Therapeutic group animals showed a significant response to drug compared to the control group by day 3 (P < 0.01). Molecular US imaging is a non-invasive, inexpensive approach for analyzing early response to vascular disrupting agents as demonstrated by this study in a breast cancer animal model.
UR - http://www.scopus.com/inward/record.url?scp=84882325367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882325367&partnerID=8YFLogxK
U2 - 10.1109/ULTSYM.2012.0576
DO - 10.1109/ULTSYM.2012.0576
M3 - Conference contribution
AN - SCOPUS:84882325367
SN - 9781467345613
T3 - IEEE International Ultrasonics Symposium, IUS
SP - 2306
EP - 2308
BT - 2012 IEEE International Ultrasonics Symposium, IUS 2012
T2 - 2012 IEEE International Ultrasonics Symposium, IUS 2012
Y2 - 7 October 2012 through 10 October 2012
ER -